{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Cell+Lung+Cancer+and+Breast+Cancer&page=21",
    "query": {
      "condition": "Small Cell Lung Cancer and Breast Cancer",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 492,
    "total_pages": 50,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Cell+Lung+Cancer+and+Breast+Cancer&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Small+Cell+Lung+Cancer+and+Breast+Cancer&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T07:12:08.082Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06726148",
      "title": "Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced HR+/HER2- Breast Cancer",
        "Advanced CCNE1-amplified Solid Tumors",
        "Extensive-stage Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "ECI830",
          "type": "DRUG"
        },
        {
          "name": "ribociclib",
          "type": "DRUG"
        },
        {
          "name": "fulvestrant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 280,
      "start_date": "2025-04-03",
      "completion_date": "2028-09-25",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-10-16T07:12:08.082Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Fort Myers, Florida • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06726148"
    },
    {
      "nct_id": "NCT03729596",
      "title": "MGC018 With or Without MGA012 in Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma of Head and Neck",
        "Triple Negative Breast Cancer",
        "Melanoma",
        "Advanced Solid Tumor, Adult",
        "Metastatic Castrate Resistant Prostate Cancer",
        "Non Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "vobramitamab duocarmazine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 143,
      "start_date": "2018-11-21",
      "completion_date": "2023-03-18",
      "has_results": true,
      "last_update_posted_date": "2025-07-31",
      "last_synced_at": "2026-10-16T07:12:08.082Z",
      "location_count": 9,
      "location_summary": "Santa Monica, California • Washington D.C., District of Columbia • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03729596"
    },
    {
      "nct_id": "NCT07705334",
      "title": "A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors",
        "Triple Negative Breast Cancer (TNBC)",
        "HR+ Breast Cancer",
        "Colon Cancer",
        "Gastric Cancer",
        "Hepatecellular Carcinoma",
        "NSCLC (Advanced Non-small Cell Lung Cancer)",
        "Mesothelioma",
        "Pancreatic Carcinoma Metastatic",
        "Hormone Refractory Prostate Cancer",
        "Soft Tissue Sarcomas"
      ],
      "interventions": [
        {
          "name": "SHY-ONC6",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SHY Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-06-24",
      "completion_date": "2028-05-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-16T07:12:08.082Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Denver, Colorado • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07705334"
    },
    {
      "nct_id": "NCT04314401",
      "title": "National Cancer Institute \"Cancer Moonshot Biobank\"",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Esophageal Carcinoma",
        "Fallopian Tube Carcinoma",
        "Gastric Carcinoma",
        "Hormone Receptor-Positive Breast Carcinoma",
        "Invasive Breast Carcinoma",
        "Lung Non-Small Cell Carcinoma",
        "Lung Small Cell Carcinoma",
        "Malignant Solid Neoplasm",
        "Melanoma",
        "Metastatic Prostate Carcinoma",
        "Multiple Myeloma",
        "Ovarian Carcinoma",
        "Ovarian High Grade Serous Adenocarcinoma",
        "Primary Peritoneal Carcinoma",
        "Stage III Fallopian Tube Cancer AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Ovarian Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Fallopian Tube Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Ovarian Cancer AJCC v8",
        "Stage IVB Prostate Cancer AJCC v8",
        "Triple-Negative Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Medical Chart Review",
          "type": "OTHER"
        },
        {
          "name": "Paracentesis",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 1600,
      "start_date": "2020-11-11",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-10-16T07:12:08.082Z",
      "location_count": 147,
      "location_summary": "Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 115 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Saraland",
          "state": "Alabama"
        },
        {
          "city": "Kingman",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04314401"
    },
    {
      "nct_id": "NCT05081609",
      "title": "A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Locally Advanced Solid Tumor",
        "Metastatic Solid Tumor",
        "Platinum-resistant Ovarian Cancer",
        "Post Anti-PD-1 Melanoma",
        "2L+ Cervical Cancer",
        "Neoadjuvant Melanoma",
        "Neoadjuvant Non-Small Cell Lung Cancer",
        "Post Anti-PD-(L)1 Non-Small Cell Lung Cancer",
        "Post Anti-PD-(L)1 Small Cell Lung Cancer",
        "Third Line or Later (3L+) HER2+ Breast Cancer",
        "Second or Third Line (2L/3L) Cervical Cancer",
        "Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)"
      ],
      "interventions": [
        {
          "name": "TransCon IL-2 β/γ",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy drug",
          "type": "DRUG"
        },
        {
          "name": "TransCon TLR7/8 Agonist",
          "type": "DRUG"
        },
        {
          "name": "Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab emtansine (T-DM1)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Ascendis Pharma Oncology Division A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 320,
      "start_date": "2022-01-11",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-16T07:12:08.082Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Springfield, Illinois • Louisville, Kentucky + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Springfield",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05081609"
    },
    {
      "nct_id": "NCT03195699",
      "title": "Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Non Small Cell Lung Cancer",
        "Hepatocellular Cancer",
        "Colorectal Cancer",
        "Gastric Adenocarcinoma",
        "Melanoma",
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "TTI-101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tvardi Therapeutics, Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 64,
      "start_date": "2017-11-15",
      "completion_date": "2024-06-24",
      "has_results": false,
      "last_update_posted_date": "2025-03-21",
      "last_synced_at": "2026-10-16T07:12:08.082Z",
      "location_count": 2,
      "location_summary": "Houston, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03195699"
    },
    {
      "nct_id": "NCT00467844",
      "title": "Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cachexia"
      ],
      "interventions": [
        {
          "name": "GTx-024",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GTx",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 159,
      "start_date": "2007-05",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2014-07-11",
      "last_synced_at": "2026-10-16T07:12:08.082Z",
      "location_count": 50,
      "location_summary": "Anchorage, Alaska • Fayetteville, Arkansas • Corona, California + 41 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Corona",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00467844"
    },
    {
      "nct_id": "NCT00620295",
      "title": "Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Colorectal Cancer",
        "Head and Neck Cancer",
        "Kidney Cancer",
        "Lung Cancer",
        "Ovarian Cancer",
        "Pancreatic Cancer",
        "Prostate Cancer",
        "Sarcoma"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "70 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "70 Years and older"
      },
      "enrollment_count": 17,
      "start_date": "2007-03",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2017-11-29",
      "last_synced_at": "2026-10-16T07:12:08.082Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00620295"
    },
    {
      "nct_id": "NCT07261631",
      "title": "Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma",
        "Non-Small Cell Lung Cancer",
        "HR+/HER2- Ductal and Lobular Breast Cancer",
        "Triple Negative Breast Cancer",
        "Colorectal Cancer",
        "Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "68Ga-NNS309",
          "type": "DRUG"
        },
        {
          "name": "177Lu-DFC413",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2025-11-24",
      "completion_date": "2029-05-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-16T07:12:08.082Z",
      "location_count": 1,
      "location_summary": "Princeton, New Jersey",
      "locations": [
        {
          "city": "Princeton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07261631"
    },
    {
      "nct_id": "NCT06400472",
      "title": "A Study of Sofe-M in Participants With Selected Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Neoplasms",
        "Endometrial Neoplasms",
        "Uterine Cervical Neoplasms",
        "Carcinoma, Non-Small-Cell Lung",
        "Triple Negative Breast Neoplasms",
        "Pancreatic Neoplasm",
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Sofe-M",
          "type": "DRUG"
        },
        {
          "name": "bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 575,
      "start_date": "2024-05-20",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-10-16T07:12:08.082Z",
      "location_count": 11,
      "location_summary": "Scottsdale, Arizona • La Jolla, California • Atlanta, Georgia + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Mineola",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06400472"
    }
  ]
}